Pacira BioSciences, Inc.
NASDAQ: PCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Pacira BioSciences, Inc. (PCRX) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2008 | $13.93M | $-41.86M | -25.41% | -325.77% | -300.62% |
| 2009 | $15.01M | $-31.71M | 18.03% | -190.24% | -211.30% |
| 2010 | $14.56M | $-27.15M | 15.70% | -153.63% | -186.44% |
| 2011 | $15.69M | $-43.33M | -6.69% | -249.23% | -276.17% |
| 2012 | $39.08M | $-52.28M | 17.77% | -126.13% | -133.77% |
| 2013 | $85.55M | $-63.91M | 35.98% | -62.29% | -74.70% |
| 2014 | $197.67M | $-13.72M | 60.82% | -2.61% | -6.94% |
| 2015 | $249.00M | $1.86M | 71.15% | 3.80% | 0.75% |
| 2016 | $276.37M | $-37.95M | 60.16% | -11.59% | -13.73% |
| 2017 | $286.63M | $-42.61M | 69.33% | -8.70% | -14.87% |
| 2018 | $337.28M | $-471000.00 | 74.25% | 4.72% | -0.14% |
| 2019 | $421.03M | $-11.02M | 74.65% | 2.49% | -2.62% |
| 2020 | $429.65M | $145.52M | 72.69% | 10.79% | 33.87% |
| 2021 | $541.53M | $41.98M | 74.10% | 16.61% | 7.75% |
| 2022 | $666.82M | $15.91M | 70.11% | 9.00% | 2.39% |
| 2023 | $674.98M | $41.95M | 72.64% | 12.99% | 6.22% |
| 2024 | $700.97M | $-99.56M | 75.69% | -10.47% | -14.20% |
| 2025 | $726.41M | $7.03M | 79.39% | 4.58% | 0.97% |
Frequently asked questions
What is Pacira BioSciences, Inc.'s revenue?
Pacira BioSciences, Inc.'s trailing twelve-month revenue is $734.86M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is PCRX?
In its most recent fiscal year, PCRX ran a gross margin of 79.39%, an operating margin of 4.58%, and a net margin of 0.97%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does PCRX generate?
PCRX produced $136.66M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is PCRX's balance sheet healthy?
PCRX holds $158.54M in cash and equivalents against $372.19M in long-term debt, on $693.11M of shareholder equity. That debt is best read against the cash flow the business throws off each year.